Talent: The Biggest Issue In Biotech Boardrooms Today

One consequence of the strong biotech IPO market is a tremendous uptick in the demand for experienced  board directors to sit on the boards of these newly public companies. In his blog on the life sciences industry, Atlas Ventures' Bruce Booth discusses findings by John Archer and Sara Hagar that quantify the growth of that supply-demand gap.